Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 519

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 519
---
,000 and $0, respectively.

Please refer to Note 5 for discussion related to notes which have passed their maturity dates.

Hana Loans

On August 1, 2024, the Company borrowed $0.9 million from Hana Immunotherapeutics, LLC (“Hana”), a related party of the Company due to having common executives (the “Hana Loans”). The

<div align='center'>F-65</div>

TABLE OF CONTENTS

LIMINATUS PHARMA, LLC NOTES TO CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2024
(Unaudited) Hana Loans bear interest at 6% per annum and was due on September 30, 2024 and October 26, 2024, which may be extended upon mutual agreement of the parties. As of September 30, 2024 and December 31, 2023, the balance of the Hana Loans is $0.9 million and $0, respectively. For the nine months ended September 30, 2024 and 2023, interest expense related to the Hana Loans was approximately $6,000 and $0, respectively. Please refer to Note 5 for discussion related to notes which have passed their maturity dates. Due to Related Party As of September 30, 2024 and December 31, 2023, the Company has $0.2 million due to the CEO of the Company for compensation under his employment agreement for both years. Viral Gene As of September 30, 2024 and December 31, 2023, the Company has $0.1 million due from Viral Gene included in due from related party in the condensed balance sheets for a short-term loan to Viral Gene and expense paid on behalf of Viral Gene. The Company’s CEO is also the CEO of Viral Gene. The loan does not bear any interest. Note 5. Debt The Company has the following debt outstanding as of September 30, 2024 and December 31, 2023 (in thousands):

| ​                                |   |   |                                       | ​ | ​ | September 30,2024 |   |        |   | ​ | ​ | December 31,2023 |   |        |   | ​ |
|:---------------------------------|:--|:--|:--------------------------------------|:--|:--|:------------------|:--|-------:|:--|:--|